drugset / Trial / NCT00181948
Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This will be a 6-week, unblinded study using the medication Strattera for children and adolescents with attention deficit hyperactivity disorder (ADHD) who failed to respond to an adequate trial of stimulant treatment. Specific hypotheses are as follows: Hypothesis 1: ADHD symptomatology in youth with ADHD will be responsive to Strattera treatment in the short term. Hypothesis 2: Strattera treatment (in doses of up to 120 mg/day or 1.2 mg/kg/day) in children and adolescents with ADHD will be safe and well tolerated.
Timeline
- Start
- 2004-09
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atomoxetine | Other / unclassified | 1.2 mg/kg | — |
| Subject | Atomoxetine | Other / unclassified | 120 mg | — |